BioAmber Inc. (BIOA) News
Filter BIOA News Items
BIOA News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
BIOA News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest BIOA News From Around the Web
Below are the latest news stories about BIOAGE LABS INC that investors may wish to consider to help them evaluate BIOA as an investment opportunity.
BioAge Labs, Inc. (BIOA) Loses -67.99% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerBioAge Labs, Inc. (BIOA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term. |
BioAge Labs, Inc. (BIOA): A Bull Case TheoryWe came across a bullish thesis on BioAge Labs, Inc. (NASDAQ:BIOA) on Value Investing Subreddit Page by value1024. In this article, we will summarize the bulls’ thesis on BIOA. BioAge Labs, Inc. (NASDAQ:BIOA)’s share was trading at $5.88 as of Dec 26th. BioAge Labs (NASDAQ:BIOA), a recent IPO in the biotech sector, has experienced significant volatility, dropping […] |
BioAge and Novartis seek drug targets for ageing-related diseasesBioAge will receive an upfront payment and research funding of up to $20m. |
BioAge Labs Announces Multi-Year Collaboration with Novartis to Discover Novel Targets for Therapies that Address Age-Related Diseases and ConditionsCollaboration will leverage BioAge's differentiated human longevity data and platform and Novartis expertise in the biology of physical exercise to identify drug targets to treat diseases related to aging Novartis to pay up to $20M comprising upfront payments and research funding; BioAge may receive up to $530M in future long-term research, development, and commercial milestones RICHMOND, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. ("BioAge"), a clinical-stage biopharmaceutical c |
3 closely watched drugs that failed in the clinicHow recent setbacks and scattered successes could impact various sectors of the industry. |
BioAge halts ongoing Phase II trial of obesity drug due to liver concernsIn the trail, 11 participants in the azelaprag group exhibited transaminase elevations without significant symptoms. |
Just Two Months After IPO, BioAge Labs Stops Eli Lilly-Collaborated Obesity Trial On Safety ConcernsOn Friday, BioAge Labs Inc. (NASDAQ:BIOA) announced that it will discontinue the ongoing STRIDES Phase 2 study of its investigational drug candidate, azelaprag. STRIDES was being conducted in collaboration with Eli Lilly And Co’s (NYSE:LLY) Chorus clinical development organization. Top-line results were anticipated in the third quarter of 2025. The move follows after liver transaminitis without clinically significant symptoms was observed in some subjects receiving azelaprag. STRIDES is a Phase |
BioAge shares tumble after decision to halt obesity drug studyThe biotech disclosed Friday plans to terminate a Phase 2 study testing azelaprag with tirzepatide for weight loss following safety concerns. |
BioAge Labs Announces Discontinuation of STRIDES Phase 2 Clinical Trial Evaluating Azelaprag in Combination with Tirzepatide for the Treatment of ObesityDecision follows observations of liver transaminitis without clinically significant symptoms in some subjects on azelaprag Company will evaluate data from patients enrolled to date and share updated plans for azelaprag in Q1 2025 In parallel to evaluating azelaprag, Company will continue to advance earlier platform-derived programs, including IND submission for CNS penetrant NLRP3 inhibitor anticipated in the second half of 2025 RICHMOND, Calif., Dec. 06, 2024 (GLOBE NEWSWIRE) -- BioAge Labs (Na |
BioAge Labs to Present at Goldman Sachs “Year-Ahead” Catalyst ClinicRICHMOND, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- BioAge Labs (Nasdaq: BIOA) (“BioAge”, “the Company”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that the Company will present at the Goldman Sachs Second Annual “Year-Ahead” Catalyst Clinic on Thursday, December 19, 2024, 11–12 PM EST. To access the live webcast of the virtual presentation, register here. Replays of the web |